Comparing Propanc Biopharma (OTCMKTS:PPCB) and Amneal Pharmaceuticals (NASDAQ:AMRX)

Propanc Biopharma (OTCMKTS:PPCBGet Free Report) and Amneal Pharmaceuticals (NASDAQ:AMRXGet Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and profitability.

Analyst Recommendations

This is a summary of current ratings for Propanc Biopharma and Amneal Pharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Propanc Biopharma 0 0 0 0 N/A
Amneal Pharmaceuticals 0 0 4 0 3.00

Amneal Pharmaceuticals has a consensus target price of $8.25, suggesting a potential upside of 27.91%. Given Amneal Pharmaceuticals’ higher probable upside, analysts clearly believe Amneal Pharmaceuticals is more favorable than Propanc Biopharma.

Institutional & Insider Ownership

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 1.8% of Propanc Biopharma shares are owned by insiders. Comparatively, 17.5% of Amneal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Propanc Biopharma and Amneal Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Propanc Biopharma N/A N/A -1,700.65%
Amneal Pharmaceuticals -6.76% 234.06% 4.27%

Valuation and Earnings

This table compares Propanc Biopharma and Amneal Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Propanc Biopharma N/A N/A -$2.66 million N/A N/A
Amneal Pharmaceuticals $2.39 billion 0.83 -$83.99 million ($0.56) -11.52

Propanc Biopharma has higher earnings, but lower revenue than Amneal Pharmaceuticals.

Risk & Volatility

Propanc Biopharma has a beta of 1.88, suggesting that its stock price is 88% more volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500.

Summary

Amneal Pharmaceuticals beats Propanc Biopharma on 7 of the 10 factors compared between the two stocks.

About Propanc Biopharma

(Get Free Report)

Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.

About Amneal Pharmaceuticals

(Get Free Report)

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Receive News & Ratings for Propanc Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Propanc Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.